379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor
Main Authors: | Gareth Betts, Natalie Bath, Mark Dudley, Tanner Johanns, Ahmed Galal, Samuel Saibil, Adrian Sacher, Spinner William, Alex Tipping, Jessica Tucci, Raymond Luke, Trupti Trivedi, Quan Lin, Karen Miller |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
Recognition of renal cell carcinoma by CD8+ and CD4+ TCR-engineered T lymphocytes
by: Turqueti Neves, Adriana
Published: (2011) -
Contrasted TCRβ diversity of CD8+ and CD8- T cells in rainbow trout.
by: Rosario Castro, et al.
Published: (2013-01-01) -
The molecular signature underlying the thymic migration and maturation of TCRαβ+ CD4+ CD8 thymocytes.
by: Fei Teng, et al.
Published: (2011-01-01) -
Distinct Features of Canine Non-conventional CD4−CD8α− Double-Negative TCRαβ+ vs. TCRγδ+ T Cells
by: Friederike V. Rabiger, et al.
Published: (2019-11-01) -
Extracellular domains of CD8α and CD8ß subunits are sufficient for HLA class I restricted helper functions of TCR-engineered CD4(+) T cells.
by: Marleen M van Loenen, et al.
Published: (2013-01-01)